Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1153-1159

  Brunetto, Maurizia R ^a   Marcellin, Patrick ^b   Cherubini, Beatrice ^a   Yurdaydin, Cihan ^c   Farci, Patrizia ^d   Hadziyannis, Stephanos J ^e   Rothe, Vivien ^f   Regep, Loredana ^g   Bonino, Ferruccio ^h  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e Evgenidion Hospital   (Greece)

^f IST GmbH   (Germany)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

Genotype; HBeAg negative chronic hepatitis B; HBsAg quantification; Peginterferon alfa 2a; Response guided

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ALANINE AMINOTRANSFERASE; ALT; CHB; CHRONIC HEPATITIS B; END-OF-TREATMENT; EOT; GENOTYPE; HBEAG; HBEAG-NEGATIVE CHRONIC HEPATITIS B; HBSAG; HBSAG QUANTIFICATION; HBV; HEPATITIS B E ANTIGEN; HEPATITIS B S ANTIGEN; HEPATITIS B VIRUS; IFN; INTERFERON; LONG-TERM VIROLOGICAL RESPONSE; LVR; NEGATIVE PREDICTIVE VALUE; NPV; PEGINTERFERON ALFA-2A; POSITIVE PREDICTIVE VALUE; PPV; RECEIVER-OPERATING CHARACTERISTIC; RESPONSE-GUIDED; ROC;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; KINETICS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84887993086     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.017     Document Type: Article

References (16)

1. S.J. Hadziyannis, and G.V. Papatheodoridis Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment Semin Liver Dis 26 2006 130 141
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
3. M.R. Brunetto, F. Oliveri, B. Coco, G. Leandro, P. Colombatto, and J.M. Gorin Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study J Hepatol 36 2002 263 270
4. G. Fattovich, F. Bortolotti, and F. Donato Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335 352
5. S.J. Hadziyannis Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy J Hepatol 36 2002 280 282
6. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
7. P. Marcellin, T. Piratvisuth, M. Brunetto, F. Bonino, G.K.K. Lau, and P. Farci Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post-treatment follow up J Hepatol 50 2009 S336
8. F. Oliveri, T. Santantonio, G. Bellati, P. Colombatto, G.C. Mels, and L. Carriero Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon Am J Gastroenterol 94 1999 1366 1372
9. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
10. E.K. Manesis, and S.J. Hadziyannis Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B Gastroenterology 121 2001 101 109
11. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
12. P. Marcellin, F. Bonino, C. Yurdaydin, S. Hadziyannis, R. Moucari, and H.-P. Kapprell Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients Hepatol Int 7 2013 88 97
13. R. Moucari, M. Martinot-Peignoux, V. Mackiewicz, N. Boyer, M.P. Ripault, and C. Castelnau Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 2009 1183 1188
14. V. Rijckborst, B.E. Hansen, P. Ferenci, M.R. Brunetto, F. Tabak, and Y. Cakaloglu Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a J Hepatol 56 2012 1006 1011
15. M. Sugiyama, Y. Tanaka, T. Kato, E. Orito, K. Ito, and S.K. Acharya Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens Hepatology 44 2006 915 924
16. P. Lampertico, M. Viganò, G.G. Di Costanzo, E. Sagnelli, M. Fasano, and V. Di Marco Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B Gut 62 2013 290 298